Ultragenyx Pharmaceutical Inc. or Perrigo Company plc: Who Invests More in Innovation?

Ultragenyx vs. Perrigo: A Decade of R&D Investment

__timestampPerrigo Company plcUltragenyx Pharmaceutical Inc.
Wednesday, January 1, 201415250000045967000
Thursday, January 1, 2015187800000114737000
Friday, January 1, 2016184000000183204000
Sunday, January 1, 2017167700000231644000
Monday, January 1, 2018218600000293998000
Tuesday, January 1, 2019187400000357355000
Wednesday, January 1, 2020177700000412084000
Friday, January 1, 2021122000000497153000
Saturday, January 1, 2022123100000705789000
Sunday, January 1, 2023122500000648449000
Loading chart...

Igniting the spark of knowledge

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Ultragenyx Pharmaceutical Inc. and Perrigo Company plc have shown contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Ultragenyx has consistently increased its R&D spending, peaking at a staggering 705% increase from its 2014 levels by 2022. This commitment underscores Ultragenyx's focus on pioneering treatments and cutting-edge research.

Conversely, Perrigo's R&D investment has seen a more conservative trajectory, with a peak in 2018 and a subsequent decline, reflecting a strategic shift towards optimizing existing product lines. By 2023, Perrigo's R&D expenses had decreased by approximately 20% from their 2018 peak.

This data highlights the divergent strategies of these two industry players, offering insights into their future directions and potential market impacts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025